ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN ...

Table I.
Minor surgical complications were observed in 12 patients
(18%), including seven lymphoceles (10%), two pelvic
hematomas (3%) and three bladder neck strictures (6%). The
mean hospital stay was 5 (range 4-8) days. At last follow-up,
all patients were alive. Discussion and Conclusion: IORT
during RP represents a safe procedure, with acceptable
surgical time and minimal toxicity for patients with locally
advanced PCa. A larger series and a longer follow-up are
needed to confirm these findings and to assess long-term sideeffects
and biochemical control.
181
MALIGNANT HISTIOCYTOMA OF THE PENIS:
A CASE REPORT
Fabio Neri, Francesco Berardinelli, Luca Cindolo,
Fabiola Raffaella Tamburro and Luigi Schips
UOC Urologia, Ospedale San Pio San da Pietrelcina, Vasto
(CH), Italy
Background: Penile malignant fibrous histiocytoma is an
extremely rare tumor, with only 5% of penile tumors being
mesenchymal tumors. We present here a four-year follow-up
of a patient affected by primary malignant fibrous
histiocytoma of the penis. To the best of our knowledge, this is
the first published report of such a case. Case Report: An
uncircumcised 64-year-old male presented in April 2007 with
a 4-cm solid lesion on the penile right base (Corporum
cavernosum). There was no history of sexually transmitted
disease, constitutional symptoms or dysuria. Physical
examination revealed the absence of palpable abnormalities in
the inguinal region. Inguinal ultrasound did not show any
abnormal nodes. Penile needle biopsy revealed a malignant
mesenchymal tumor. This case was treated surgically with
total penectomy. Histopathological examination concluded the
tumor was a G2 malignant histiocytoma, with negative
surgical margins. Immunohistochemical stains were positive
for vimentin and negative for cytokeratin, desmin, S-100,
AE1/AE3, CK34, Be12, actin, desmin, CD31, CD34 and p63.
Results and Conclusion: At the 4-year follow-up, the patient
was in very good condition, without local or distant
ANTICANCER RESEARCH 31: 1807-1956 (2011)
% UTI Mild Severe Urethral Bladder AUR Recto-urinary
incontinence I-II incontinence III stenosis neck strictures fistula
All patients 14 21 3 7 10 8 1
Group A 11 18 3 7 8 6 1
Group B 3 3 0 0 2 2 0
UTI: Urinary tract infection; AUR: acute urinary retention.
1908
metastasis, and with normal uroflowmetry is normal He has,
however, developed a depressive syndrome mainly related to
the absence of a penis. Malignant fibrous histiocytoma is
rarely reported in the literature and primary involvement of the
genitourinary tract is very rare. Because of the rarity of such
tumors, there is no agreement concerning the best method for
staging and management of these patients.
1 Parsons MA and Fox M: Malignant fibrous histiocytoma of
the penis. Eur Urol 14: 75-76, 1988.
2 Moran CA and Kaneko M: Malignant fibrous histiocytoma
of the glans penis. Am J Dermatopathol 12: 182-187, 1990.
3 Tripathi VNP and Dick VS: Primary sarcoma of the urogenital
system in adults. J Urol 101: 898-904, 1969.
4 Zaffagnini V: Il sarcoma del pene. Contributo anatomoclinico
e sintesi bibliografica. Arch Ital Anat Istol Pat 37:
322-339, 1963.
182
CAN SPLITTING TURP AND
HIFU INTO TWO SESSIONS
REDUCE COMPLICATION RATES?
Roberto Sanseverino, Olivier Intilla, Giorgio Napodano,
Umberto Di Mauro and Tommaso Realfonso
U.O.C. Urologia, Ospedale Umberto I, ASL Salerno, Nocera
Inferiore, Salerno, Italy
Aim: To evaluate whether splitting transurethral resection of
the prostate (TURP) and high-intensity focused ultrasound
(HIFU) into two sessions can reduce complication rates in
patients with localized prostate cancer. Patients and
Methods: From November 2004 to September 2010, 103
patients affected by localized prostate cancer underwent
HIFU following TURP. In 39 patients, both procedures were
performed in the same session (Group A); in 64 patients,
HIFU was delayed (Group B). Follow-up included serial
PSA measurements and prostate biopsies 6 months after
treatment for all patients. Biochemical recurrence was
defined as PSA nadir + 2 ng/ml (ASTRO 2005 criteria). We
evaluated complication rates in Groups A and B. Results: